VBI Vaccines Inc. (VBIV)
Largest Insider Buys in Sector
VBIV Stock Price History Chart
VBIV Stock Performance
About VBI Vaccines Inc.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.
Insider Activity of VBI Vaccines Inc.
Over the last 12 months, insiders at VBI Vaccines Inc. have bought $1M and sold $0 worth of VBI Vaccines Inc. stock.
On average, over the past 5 years, insiders at VBI Vaccines Inc. have bought $7.05M and sold $5.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILLIS STEVEN (director) — $3.01M.
The last purchase of 609,090 shares for transaction amount of $1M was made by GILLIS STEVEN (director) on 2023‑07‑10.
List of Insider Buy and Sell Transactions, VBI Vaccines Inc.
| 2023-07-10 | GILLIS STEVEN | director | 609,090 7.9882% | $1.65 | $1M | -57.53% | ||
| 2023-04-06 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 4.25M 1.3215% | $0.11 | $467,672 | -83.57% | |
| 2023-04-05 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1.83M 0.7547% | $0.13 | $238,233 | -80.83% | |
| 2023-04-04 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 4.81M 2.1131% | $0.16 | $769,700 | -83.57% | |
| 2021-12-03 | Beattie Nell | Chief Business Officer | 8,200 0.0033% | $2.45 | $20,083 | -58.16% | ||
| 2021-12-01 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 2.71M 1.1266% | $3.31 | $8.96M | -67.79% | |
| 2021-06-29 | Sale | PERCEPTIVE ADVISORS LLC | director | 145,548 0.0019% | $3.80 | $553,082 | -37.63% | |
| 2021-06-09 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1.42M 0.019% | $4.00 | $5.69M | -36.32% | |
| 2020-04-24 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 9.09M 0.1372% | $1.10 | $10M | +175.00% | ||
| 2019-10-04 | Diaz-Mitoma Francisco | Chief Medical Officer | 40,000 0.0007% | $0.50 | $20,000 | +169.81% | ||
| 2019-10-01 | Beattie Nell | Chief Business Officer | 10,000 0.0002% | $0.48 | $4,822 | +195.83% | ||
| 2019-10-01 | McNulty Christopher | CFO and Head of BD | 12,000 0.0002% | $0.47 | $5,676 | +195.83% | ||
| 2019-09-30 | Baxter Jeff | CEO, President | 150,000 0.003% | $0.50 | $75,450 | +202.13% | ||
| 2019-09-30 | Diaz-Mitoma Francisco | Chief Medical Officer | 14,500 0.0003% | $0.50 | $7,250 | +202.13% | ||
| 2019-09-23 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 20M 0.6147% | $0.50 | $10M | +170.59% | ||
| 2019-06-27 | Diaz-Mitoma Francisco | Chief Medical Officer | 8,000 0.0003% | $1.07 | $8,560 | -14.55% | ||
| 2019-06-20 | Diaz-Mitoma Francisco | Chief Medical Officer | 52,000 0.0016% | $0.87 | $45,180 | -1.05% | ||
| 2019-06-19 | Baxter Jeff | CEO, President | 144,000 0.0046% | $0.73 | $105,336 | +18.99% | ||
| 2019-06-19 | Beattie Nell | Chief Business Officer | 8,000 0.0003% | $0.74 | $5,886 | +18.99% | ||
| 2019-06-18 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1M 0.0331% | $0.65 | $650,000 | +40.30% |
Insider Historical Profitability
| GILLIS STEVEN | director | 1043292 4.4044% | $0.64 | 2 | 0 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 41440729 174.9462% | $0.64 | 6 | 6 | +85.55% |
| CHAWLA SAM | director | 9345725 39.4539% | $0.64 | 1 | 0 | <0.0001% |
| Opko Health, Inc. | 10 percent owner | 6678752 28.195% | $0.64 | 1 | 0 | <0.0001% |
| Kariv Tomer | director | 1744969 7.3666% | $0.64 | 1 | 0 | |
| Baxter Jeff | CEO, President | 608255 2.5678% | $0.64 | 11 | 0 | +15.57% |
| Diaz-Mitoma Francisco | Chief Medical Officer | 117500 0.496% | $0.64 | 8 | 0 | +56.46% |
| Beattie Nell | Chief Business Officer | 68200 0.2879% | $0.64 | 4 | 0 | +52.22% |
| McNulty Christopher | CFO and Head of BD | 37000 0.1562% | $0.64 | 1 | 0 | +195.83% |
Institutional Investor Ownership
No records found… | |||||||